U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H31NO
Molecular Weight 349.5099
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ABIRATERONE

SMILES

C[C@@]12CC[C@@]([H])(CC2=CC[C@@]3([H])[C@]4([H])CC=C(c5cccnc5)[C@@]4(C)CC[C@@]31[H])O

InChI

InChIKey=GZOSMCIZMLWJML-VJLLXTKPSA-N
InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H31NO
Molecular Weight 349.5099
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002321/WC500112860.pdf

Abiraterone acetate (trade name Zytiga) is a prodrug to the abiraterone, steroidal compound with antiandrogen activity and a 17 α-hydroxylase/C17,20-lyase (CYP17) inhibitor. It is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone acetate is converted in vivo to abiraterone which inhibits CYP17, enzyme expressed in testicular, adrenal, and prostatic tumor tissues and required for androgen biosynthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor.

CNS Activity

Curator's Comment:: Abiraterone was able to cross the blood brain barrier since 14C-abiraterone had been measured in the cerebellum, cerebrum, medulla and spinal cord.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
110.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZYTIGA

Approved Use

Indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Launch Date

1.30394882E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
226 ng/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
297 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12.5 ng/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
50.2 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
60.6 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
85.7 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
71.9 ng/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
64.5 ng/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1173 ng × h/mL
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1562 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
177 ng × h/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
315 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
315 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
330 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
365 ng × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
461 ng × h/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.6 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18.2 h
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.2 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18.2 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.1 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17.7 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15.4 h
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ABIRATERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Disc. AE: Cardiac failure, AST high...
Other AEs: Lymphopenia, Lymphopenia...
AEs leading to
discontinuation/dose reduction:
Cardiac failure (5 patients)
AST high (1%)
ALT high (1%)
Other AEs:
Lymphopenia (grade 1-2, 29.3%)
Lymphopenia (grade 3-4, 8.7%)
Hyperglycemia (grade 1-2, 50.5%)
Hyperglycemia (grade 3-4, 6.5%)
ALT high (grade 1-2, 35.9%)
ALT high (grade 3-4, 6.1%)
AST high (grade 1-2, 33.9%)
AST high (grade 3-4, 3.1%)
Hypernatremia (grade 1-2, 32.6%)
Hypernatremia (grade 3-4, 0.4%)
Hypokalemia (grade 1-2, 14.2%)
Hypokalemia (grade 3-4, 2.8%)
Cardiac failure (grade 3-4, 1.6%)
Cardiac failure (grade 5, 2 patients)
Sources:
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Other AEs: Fatigue, Fatigue...
Other AEs:
Fatigue (grade 1-2, 39%)
Fatigue (grade 3-4, 2.2%)
Edema peripheral (grade 1-2, 25%)
Pitting edema (grade 1-2, 25%)
Generalized edema (grade 1-2, 25%)
Pyrexia (grade 1-2, 8.7%)
Pyrexia (grade 3-4, 0.6%)
Arthritis (grade 1-2, 30%)
Arthralgia (grade 1-2, 30%)
Joint swelling (grade 1-2, 30%)
Joint stiffness (grade 1-2, 30%)
Groin pain (grade 1-2, 6.6%)
Constipation (grade 1-2, 23%)
Diarrhea (grade 1-2, 22%)
Dyspepsia (grade 1-2, 11%)
Hot flush (grade 1-2, 22%)
Hot flush (grade 3-4, 0.2%)
Hypertension (grade 1-2, 22%)
Hypertension (grade 3-4, 3.9%)
Cough (grade 1-2, 17%)
Dyspnea (grade 1-2, 12%)
Dyspnea (grade 3-4, 2.4%)
Insomnia (grade 1-2, 14%)
Insomnia (grade 3-4, 0.2%)
Contusion (grade 1-2, 13%)
Fall (grade 1-2, 5.9%)
Upper respiratory tract infection (grade 1-2, 13%)
Nasopharyngitis (grade 1-2, 8%)
Hematuria (grade 1-2, 10%)
Hematuria (grade 3-4, 1.3%)
Rash (grade 1-2, 8.1%)
Sources:
2000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 1 times / day
Sources: Page: p. 27
unhealthy
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Sex: M
Sources: Page: p. 27
AEs

AEs

AESignificanceDosePopulation
ALT high 1%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
AST high 1%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Cardiac failure 5 patients
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypokalemia grade 1-2, 14.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Lymphopenia grade 1-2, 29.3%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypernatremia grade 1-2, 32.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
AST high grade 1-2, 33.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
ALT high grade 1-2, 35.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hyperglycemia grade 1-2, 50.5%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypernatremia grade 3-4, 0.4%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Cardiac failure grade 3-4, 1.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hypokalemia grade 3-4, 2.8%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
AST high grade 3-4, 3.1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
ALT high grade 3-4, 6.1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hyperglycemia grade 3-4, 6.5%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Lymphopenia grade 3-4, 8.7%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Cardiac failure grade 5, 2 patients
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 542
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 542
Sources:
Hematuria grade 1-2, 10%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Dyspepsia grade 1-2, 11%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Dyspnea grade 1-2, 12%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Contusion grade 1-2, 13%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Upper respiratory tract infection grade 1-2, 13%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Insomnia grade 1-2, 14%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Cough grade 1-2, 17%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Diarrhea grade 1-2, 22%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hot flush grade 1-2, 22%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hypertension grade 1-2, 22%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Constipation grade 1-2, 23%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Edema peripheral grade 1-2, 25%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Generalized edema grade 1-2, 25%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Pitting edema grade 1-2, 25%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Arthralgia grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Arthritis grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Joint stiffness grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Joint swelling grade 1-2, 30%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Fatigue grade 1-2, 39%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Fall grade 1-2, 5.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Groin pain grade 1-2, 6.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Nasopharyngitis grade 1-2, 8%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Rash grade 1-2, 8.1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Pyrexia grade 1-2, 8.7%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hot flush grade 3-4, 0.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Insomnia grade 3-4, 0.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Pyrexia grade 3-4, 0.6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hematuria grade 3-4, 1.3%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Fatigue grade 3-4, 2.2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Dyspnea grade 3-4, 2.4%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Hypertension grade 3-4, 3.9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
Corticosteroid
Sources:
unhealthy, 70 years
n = 546
Health Status: unhealthy
Condition: metastatic castrationresistant prostate cancer
Age Group: 70 years
Sex: M
Population Size: 546
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
strong [Ki 0.16 uM]
yes (co-administration study)
Comment: The systemic exposure of dextromethorphan (CYP2D6 substrate) as assessed by the ratios of the geometric mean for Cmax and AUC, were approximately 2.8- and 2.9-fold higher, respectively, when dextromethorphan was co-administered with abiraterone acetate
Page: 8.0
strong [Ki 0.32 uM]
yes [IC50 10.8 uM]
yes [Ki 0.12 uM]
yes [Ki 0.39 uM]
yes [Ki 0.44 uM]
yes [Ki 11.4 uM]
yes [Ki 17.6 uM]
yes [Ki 29.8 uM]
yes [Ki 31.8 uM]
yes [Ki 46.3 uM]
yes [Ki 8.01 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer.
2010 Jul
Abiraterone acetate.
2011 Aug 1
[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
2012 Feb
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men.
2012 Jun
Differential response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal testis xenograft bioassay.
2014 Mar
Patents

Sample Use Guides

1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily. Zytiga must be taken on an empty stomach. No food should be consumed for at least two hours before the dose of Zytiga is taken and for at least one hour after the dose of Zytiga is taken. For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the Zytiga starting dose to 250 mg once daily. For patients who develop hepatotoxicity during treatment, hold Zytiga until recovery. Retreatment may be initiated at a reduced dose. Zytiga should be discontinued if patients develop severe hepatotoxicity.
Route of Administration: Oral
Abiraterone acetate (CB 7630) inhibits CYP17 with an IC50 of 110 nM in human testicular microsomes. In Caco-2 cell monolayers abiraterone acetate had a low apparent permeability and was not substrate of P-glycoprotein (P-gp). Abiraterone acetate inhibited P-gp significantly at high concentrations with a 50 % inhibitory concentration (IC50) of 10.8 uM however as abiraterone acetate is rapidly converted to abiraterone, no systemic inhibition of P-gp is expected.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:48:56 UTC 2021
Edited
by admin
on Fri Jun 25 21:48:56 UTC 2021
Record UNII
G819A456D0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ABIRATERONE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NSC-741232
Code English
17-(3-PYRIDYL)ANDROSTA-5,16-DIEN-3.BETA.-OL
Systematic Name English
ABIRATERONE [USP]
Common Name English
ABIRATERONE [WHO-DD]
Common Name English
CB 7598
Code English
ABIRATERONE [VANDF]
Common Name English
ABIRATERONE [MI]
Common Name English
CB-7598
Code English
ANDROSTA-5,16-DIEN-3-OL, 17-(3-PYRIDINYL)- (3.BETA.)-
Systematic Name English
ABIRATERONE [INN]
Common Name English
Classification Tree Code System Code
LIVERTOX 4
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
NDF-RT N0000182633
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
WHO-VATC QL02BX03
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
NCI_THESAURUS C147923
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
WHO-ATC L02BX03
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
Code System Code Type Description
DRUG BANK
DB05812
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
MESH
C089740
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
RXCUI
1100072
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY RxNorm
EVMPD
SUB07361MIG
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
INN
7375
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
CAS
154229-19-3
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
IUPHAR
6745
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
FDA UNII
G819A456D0
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
ChEMBL
CHEMBL254328
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
WIKIPEDIA
ABIRATERONE
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
MERCK INDEX
M1279
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY Merck Index
NDF-RT
N0000187062
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY Cytochrome P450 2C8 Inhibitors [MoA]
NCI_THESAURUS
C77333
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
PUBCHEM
132971
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY
NDF-RT
N0000182632
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY Cytochrome P450 17A1 Inhibitors [MoA]
NDF-RT
N0000182137
Created by admin on Fri Jun 25 21:48:56 UTC 2021 , Edited by admin on Fri Jun 25 21:48:56 UTC 2021
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
METABOLIC ENZYME -> INHIBITOR
Abiraterone is an inhibitor of CYP2D6, in vivo. In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
EXCRETED UNCHANGED
FECAL
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
WEAK
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE INACTIVE -> PARENT
The conversion is likely through esterase activity (the esterases have not been identified) and is not CYP mediated.
MAJOR
PLASMA
PRODRUG -> METABOLITE ACTIVE
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA; URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC